Zepbound Weight Loss in Newport Beach, CA

When the SURMOUNT-1 trial results were published in 2022, they redrew the boundary of what weight loss medicine can achieve. Tirzepatide, the active ingredient in Zepbound, produced average weight loss of 20.9 percent of body weight at the highest dose over 72 weeks. At Adonis Saremi, MD, Newport Beach patients access Zepbound therapy through a fully physician-supervised program led by Dr. Adonis Saremi, with clinical oversight matched to the power of this treatment.

Understanding Zepbound: The Science Behind the Results

Zepbound (tirzepatide) is the first FDA-approved dual GIP and GLP-1 receptor agonist for chronic weight management in adults. Unlike semaglutide’s single-pathway activation, tirzepatide simultaneously engages both GIP and GLP-1 receptors, amplifying appetite suppression and driving greater visceral fat reduction.

Zepbound’s Mechanisms of Action

• Dual incretin receptor activation. Synergistic metabolic effects beyond what either pathway achieves alone.
• Amplified appetite suppression. More complete hunger signal inhibition than GLP-1 monotherapy.
• Preferential fat loss. Significant reductions in both visceral and subcutaneous adipose tissue.
• Cardiometabolic normalization. Blood pressure, triglyceride, and inflammatory marker reductions.

Is Zepbound the Right Choice for You in Newport Beach?

• Patients who completed semaglutide with good but insufficient results and want to escalate to a more potent dual-agonist approach
• Those with type 2 diabetes, pre-diabetes, or significant insulin resistance who need a medication addressing both weight and metabolic dysfunction
• High-performing individuals in Newport Beach who want a science-first, results-driven weight loss protocol with clinical accountability
• Patients with BMI of 27-plus with qualifying health conditions who want tirzepatide properly managed, not just prescribed

Specialized Incretin Pharmacology Expertise

Optimal dual agonist management requires more than writing a prescription. Dr. Adonis Saremi’s expertise in incretin pharmacology ensures every Newport Beach patient’s Zepbound program is calibrated precisely to their clinical profile, not a standard template.

Begin your Zepbound program in Newport Beach. Call (949) 288-3135 or schedule your consultation online.

Frequently Asked Questions

How does Zepbound compare to Ozempic and Wegovy?

Zepbound activates two incretin receptors (GLP-1 and GIP), while Ozempic and Wegovy target GLP-1 only. The dual mechanism produces approximately 20 percent average weight loss versus 15 percent for semaglutide at comparable timeframes.